Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer

Shots:

The P-III (SKYSCRAPER-01) study evaluating tiragolumab + Tecentriq vs Tecentriq alone in a ratio (1:1) in 534 patients with PD-L1-high LA or metastatic NSCLC
The study failed to meet its co-primary EPs of PFS & the other co-primary EPs of OS were immature, numerical improvement was identified in both co-primary EPs. The results demonstrated that the therapy was well-tolerated and no new safety signals were reported
The program continues to advance the therapy for multiple clinical trials & expand into earlier stages of the disease. The company focuses to develop novel therapeutic options for malignancies that are advanced and difficult to treat in patients with a high unmet medical needs

Ref: Roche | Image: Roche

Category: News